Barclays raised the firm’s price target on Repligen (RGEN) to $175 from $160 and keeps an Overweight rating on the shares following the earnings report. The company’s outlook downshift or next year is driven by a lower market growth outlook based on peer commentary, but there is potential upside, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen Corporation Reports Strong Q3 2025 Results
- Repligen’s Strong Performance and Strategic Growth Initiatives Earn ‘Buy’ Rating
- Repligen’s Strong Q3 Performance and Upward Revenue Guidance Justify Buy Rating
- Repligen sees FY25 adjusted EPS $1.65-$1.68, consensus $1.69
- Repligen reports Q3 adjusted EPS 46c, consensus 42c